Novo Nordisk expressed confidence that its Type 2 diabetes drug liraglutide is as effective as Eli Lilly & Co.'s Byetta drug in treating the disease. The company is planning to bolster its U.S. sales force to promote its drug to general practitioners -- a move that could give the firm a competitive advantage over a long-acting version of Byetta, a Novo Nordisk official said at a health summit.

Full Story:

Related Summaries